[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"SightGlass Vision, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":105},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,44,62,86],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100610574","mobility-performance-in-daily-activities-among-children-wearing-spectacle-lenses-100610574",false,"NCT07229352","Mobility Performance in Daily Activities Among Children Wearing Spectacle Lenses","Mobility Performance in Daily Activities Among Children Wearing Single Vision and Myopia Control Spectacle Lenses","Inclusion Criteria:\n\nA participant is eligible for inclusion in the study if they meet the following criteria:\n\n* Are between the ages of 6 and 12 years of age (inclusive) at the time of informed consent\u002Fassent.\n* Can achieve a corrected visual acuity of 20\u002F20 best-corrected (or equivalent logMAR).\n* Have undergone a self-reported oculo-visual examination within the past two years.\n* Have no active ocular disease.\n* Are willing and able to adhere to instructions, study procedures, and maintain the appointment schedule.\n* Have not previously worn or participated in myopia control contact lenses for more than one month and are not currently undergoing any form of myopia control treatment.\n* The subject's parent(s) or legal guardian(s) must read, understand, and sign the Statement of Informed Consent and receive a fully executed copy of the form.\n\nExclusion Criteria:\n\nA participant will be excluded from the study if they meet any of the following conditions:\n\n* Have any systemic disease that affects ocular health.\n* Are currently using or have used, within the past 7 days, any systemic or topical medications that may impact ocular health.\n* Are currently using or have used any topical ophthalmic agents with anti-muscarinic properties within 7 days prior to enrollment or at any point during the study. This includes, but is not limited to, atropine, scopolamine, pirenzepine, tropicamide, cyclopentolate, and homatropine.\n* Have used any oral agents with anti-muscarinic properties for a chronic period (2 months or more) or short-term (within 7 days prior to enrollment). This includes, but is not limited to, gastrointestinal anti-spasmodic medications containing atropine, hyoscyamine, and dicyclomine.\n* Have known developmental delays.\n* Have participated in another clinical study in the last 7 days",true,"ALL","6 Years","12 Years",{"count":21,"type":22},20,"ESTIMATED","INTERVENTIONAL",[25],"NA","The aim of this study is evaluate and compare the mobility performance of children in daily activities while wearing single vision spectacle lenses (control) versus myopia control spectacle lenses (test).",[28,29,30],"Myopia","Myopia Progression","Juvenile Myopia","RECRUITING","2026-04-29",{"date":34,"type":35},"2026-04-30","ACTUAL",{"date":37,"type":35},"2026-02-02",{"date":39,"type":22},"2027-07-01",{"name":41,"class":42},"SightGlass Vision, Inc.","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":16,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":23,"phases":54,"briefSummary":55,"conditions":56,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":61,"locationsCount":43},"100610575","childrens-viewing-behavior-100610575","NCT07229365","Children's Viewing Behavior","Children's Viewing Behavior in Myopia Control Spectacles","Inclusion Criteria:\n\nA person is eligible for inclusion in the study if he\u002Fshe:\n\n* Is 7-14 years of age, inclusive\n* Requires spherical spectacle lenses within the power range available for the study lenses\n* Parent\u002Fguardian has read and understood the informed consent form, and the child has provided age-appropriate assent\n* Is willing and able to follow instructions and maintain the appointment schedule\n* Is correctable to a visual acuity of 20\u002F40 or better (in each eye) with their habitual vision correction or 20\u002F20 best corrected\n* Has had a self-reported oculo-visual examination in the last two years\n* Spectacle cylinder of ≤ -0.75DC in both eyes\n\nExclusion Criteria:\n\nA person will be excluded from the study if he\u002Fshe:\n\n* Is unable to complete the necessary study activities\n* Has any systemic disease affecting ocular health\n* Is using any systemic or topical medications (including pharmaceutical myopia control therapy) that will affect ocular health\n* Is aphakic","7 Years","14 Years",{"count":21,"type":22},[25],"The aim of this study is to investigate the area of the spectacle lens in which a subject is viewing through regardless of task being performed.",[28,29,30],{"date":34,"type":35},{"date":59,"type":35},"2025-12-22",{"date":39,"type":22},{"name":41,"class":42},{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":16,"sex":17,"minAge":70,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":23,"phases":74,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":85},"100593558","assessment-of-dot-spectacles-in-chinese-children-extension-100593558","NCT07008001","Assessment of DOT Spectacles in Chinese Children Extension","Clinical Assessment of DOT Spectacle Lenses in Chinese Children Extension","CATHAY Ext","Inclusion Criteria:\n\n1. Previously a successfully completed participant in the CATHAY study (NCT05562622)\n2. Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day)\n3. Willingness to participate in the trial for 12 months without contact lens wear or any other myopia management intervention\n4. The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form\n\nExclusion Criteria:\n\n1\\. Known allergy to proparacaine, tetracaine, or tropicamide or cyclopentolate","8 Years","16 Years",{"count":73,"type":22},175,[25],"This is a randomized, controlled, open-label, evaluator-blinded, multicenter, clinical trial of 12-months duration to evaluate the continued safety and efficacy of Diffusion Optics Technology (DOT) spectacle lenses in reducing the progression of juvenile myopia in children of Chinese origin.",[30,28],"2025-12-24",{"date":79,"type":35},"2025-12-29",{"date":81,"type":35},"2025-08-01",{"date":83,"type":22},"2026-12-31",{"name":41,"class":42},5,{"id":87,"slug":88,"hasResults":11,"nctId":89,"briefTitle":90,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":70,"enrollmentInfo":93,"targetDuration":4,"studyType":23,"phases":95,"briefSummary":96,"conditions":97,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":98,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":104},"100518729","efficacy-in-controlling-myopia-in-young-children-using-a-novel-spectacle-lens-100518729","NCT06034327","Efficacy in Controlling Myopia in Young Children Using a Novel Spectacle Lens","EUCALYPTUS","Inclusion Criteria:\n\n1. Children 6 - 8 years of age (inclusive) at time of informed consent\u002Fassent;\n2. Spherical equivalent refractive error between -0.75 and -4.50 D inclusive (by manifest refraction) in each eye;\n3. Astigmatism if present, less than or equal to -1.25 DC (by manifest refraction) in each eye;\n4. Best corrected visual acuity by manifest refraction of +0.10 logMAR (20\u002F25 Snellen equivalent) or better in each eye;\n5. The difference in spherical equivalent power between the two eyes (anisometropia based on manifest refraction) must be less than or equal to 1.50 D;\n6. Agree to wear the assigned spectacles constantly except for sleeping, swimming, or other activities in which spectacle wear would be dangerous or otherwise not possible (minimum of 10 hours per day);\n7. Ability to comply with study procedures, including high and low contrast visual acuity, axial length, and cycloplegic autorefraction measurements taken for both eyes at the baseline visit;\n8. Willingness to participate in the trial for 24 months without contact lens wear;\n9. The subject's parent(s) or legal guardian(s) must read, understand and sign the Statement of Informed Consent and receive a fully executed copy of the form.\n\nExclusion Criteria:\n\n1. Subject has previously or currently wears contact lenses (greater than 1-month usage);\n2. Current or prior use of bifocals, progressive addition spectacle lenses\n3. Current or prior use of any myopia control treatment (e.g., atropine, multifocal contact lenses, orthokeratology);\n4. Amblyopia in either eye;\n5. Strabismus by cover test at far (4 m) or near (40 cm) wearing distance correction;\n6. Any ocular or systemic conditions that could influence refractive development or status \\[e.g., keratoconus, congenital glaucoma, ocular trauma, diabetes, Marfan syndrome or other connective tissue disorder, Down's syndrome, family history of poor night vision (to prevent against enrolling subjects with congenital stationary night blindness)\\];\n7. Known allergy to proparacaine, tetracaine, or tropicamide;\n8. Participation in any investigational clinical study within 30 days of the Baseline visit;\n9. Subject's sibling or other household member is already enrolled in this trial.",{"count":94,"type":22},150,[25],"This is a conventional efficacy trial to validate the results from previous clinical trials for younger children; the 12-month efficacy results will be used to predict the 3-year treatment efficacy.\n\nThis is a randomized, controlled (1:1), multisite, subject- and observer-masked, 2-arm parallel group study.",[28,30,29],{"date":79,"type":35},{"date":100,"type":35},"2023-09-18",{"date":102,"type":22},"2027-03-31",{"name":41,"class":42},14,""]